Five Cancer-Specific Testing Panels

• Non-Small Cell Lung Cancer: This test analyzes 50 genes relevant to the treatment of non-small cell lung cancer. It provides reference information for precision targeted therapy selection for newly diagnosed or first-line and second-line treatment-resistant non-small cell lung cancer patients.
• Colorectal Cancer: This test analyzes 23 genes associated with targeted therapy for colorectal cancer. It provides reference information for drug selection in colorectal cancer patients considering targeted treatment.
• Gastric Cancer: This test analyzes 20 genes relevant to the treatment of gastric cancer. It provides reference information on approved targeted therapies, exploration of relevant resistance mechanisms, and off-label targeted therapy options for newly diagnosed or targeted therapy-resistant gastric cancer patients.
• Gastrointestinal Stromal Tumor: This test analyzes 20 genes associated with the treatment of gastrointestinal stromal tumors. It provides reference information on approved targeted therapies, exploration of relevant resistance mechanisms, and off-label targeted therapy options for newly diagnosed or targeted therapy-resistant gastrointestinal stromal tumor patients.
• Liver Cancer: This test analyzes 35 genes relevant to the treatment of hepatocellular carcinoma. It provides reference information on potential targeted drugs or off-label drug therapies for hepatocellular carcinoma patients.

Cancer + Precision Treatment Testing Panel

For patients with solid tumors (excluding brain tumors) seeking targeted therapy, or those with solid tumors whose radiotherapy and chemotherapy have been ineffective and are seeking immunotherapy, this panel provides information on clinically relevant biomarkers and genomic alterations. This information helps match patients with approved targeted therapies, immunotherapies, and clinical trial options, as well as assess the risk of hereditary cancers.

This panel offers robust and actionable evidence for physicians and patients to develop precision treatment strategies for cancer.

It analyzes 689 genes and genomic features, including Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).

The panel provides interpreted drug guidance, encompassing 11 immunotherapies, 360 targeted therapies, and 11 conventional therapies.